Henry Schein Inc. (NASDAQ:HSIC) was upgraded by equities research analysts at Goldman Sachs Group Inc. from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $185.00 price target on the stock. Goldman Sachs Group Inc.’s price target suggests a potential upside of 16.76% from the company’s current price.
HSIC has been the subject of a number of other research reports. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a research report on Tuesday, September 20th. Bank of America Corp. started coverage on Henry Schein in a research report on Monday, September 12th. They set a “buy” rating and a $185.00 price objective for the company. Finally, Robert W. Baird restated an “outperform” rating and set a $176.00 price objective (up previously from $175.00) on shares of Henry Schein in a research report on Tuesday, October 4th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $160.50.
Henry Schein (NASDAQ:HSIC) opened at 158.45 on Tuesday. The stock has a market cap of $12.96 billion, a PE ratio of 26.84 and a beta of 1.05. The stock has a 50 day moving average price of $162.49 and a 200-day moving average price of $170.27. Henry Schein has a 12 month low of $140.11 and a 12 month high of $183.00.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.01. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The business earned $2.87 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the previous year, the firm posted $1.46 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. On average, analysts expect that Henry Schein will post $6.57 EPS for the current year.
In related news, Director Paul Brons sold 3,381 shares of the company’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $164.03, for a total transaction of $554,585.43. Following the transaction, the director now directly owns 13,715 shares of the company’s stock, valued at $2,249,671.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.27% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of HSIC. Genesee Valley Trust Co. acquired a new position in Henry Schein during the third quarter valued at $261,000. Atria Investments LLC acquired a new position in Henry Schein during the third quarter valued at $229,000. Legacy Private Trust Co. raised its position in Henry Schein by 4.2% in the third quarter. Legacy Private Trust Co. now owns 6,640 shares of the company’s stock valued at $1,082,000 after buying an additional 270 shares during the last quarter. Creative Planning raised its position in Henry Schein by 8.3% in the third quarter. Creative Planning now owns 7,065 shares of the company’s stock valued at $1,151,000 after buying an additional 539 shares during the last quarter. Finally, Waverton Investment Management Ltd raised its position in Henry Schein by 124.1% in the third quarter. Waverton Investment Management Ltd now owns 38,731 shares of the company’s stock valued at $6,312,000 after buying an additional 21,447 shares during the last quarter. 91.98% of the stock is currently owned by hedge funds and other institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.